Hypofractionated External-Beam Radiotherapy for Prostate Cancer

Operating Procedure: Clinical Commissioning Policy: Hypofractionated external beam radiotherapy in the treatment of localised prostate cancer (adults)

Early toxicity of moderate hypofractionated volumetric modulated Arc radiotherapy for localized prostate cancer

Background: Based on the radiation biology model of prostate cancer, hypofractionated radiotherapy can improve the treatment outcomes without increasing toxicity. Although hypofractionated radiotherapy is implemented over a short period of time, it is more convenient and cheaper compared with conventional fractionated treatment. The aim of this study was to investigate the early toxicity of mod...

Review of Hypofractionated Radiotherapy for Prostate Cancer

Hypofractionated radiotherapy for prostate cancer has become of increasing interest with the recognition of a potential improvement in therapeutic outcome with treatments delivered in large-sized daily fractions. In addition, hypofractionation offers a reduction in fraction number and produces attractive cost and increased convenience for patients. There is convincing evidence, by several clini...

Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis

BACKGROUND The purpose of this work was to conduct a systematic review and meta-analysis of all randomized controlled trials comparing the efficacy and side effect profile of hypofractionated versus conventional external-beam radiation therapy for prostate cancer. METHODS Several databases were searched, including Medline, EmBase, LiLACS, and Central. The endpoints were freedom from biochemic...

Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy.

Conventionally fractionated (CF) external-beam radiation therapy (1.8-2.0 Gy/fraction) is an established treatment modality for localized prostate cancer. Emerging evidence suggests that the α/β ratio for prostate cancer is as low as 1.5, which has prompted investigators to explore hypofractionated (HF) radiation therapy. We reviewed the current status of hypofractionation and found that the ac...